Aquestive Therapeutics, Inc. AQST
4.68
(0.14)
(2.90%)
as of 25 Sep
- Market cap
- $605.0M
- P/E
- 0.0×
Follow AQST
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
278.54% | 178.61% | 145.10% | 121.12% | |
| (50.44%) | (63.99%) | (56.63%) | (69.29%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(53.05%) | (79.38%) | (67.38%) | (73.82%) | |
Average Days of Receivables |
99.25 | 145.55 | 49.86 | 62.94 | |
Free Cash Flow per Share |
(0.46) | (0.50) | (0.36) | (0.37) | |
Free Cash Flow |
(50.94) | (52.99) | (44.32) | (45.95) | |
Capital Expenditures |
(0.49) | (0.56) | (0.48) | (0.58) | |
Piotroski F-Score |
2.00 | 2.00 | 2.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(32.57%) | (45.58%) | (43.07%) | (49.01%) | |
Accounts Receivable Turnover |
4.04 | 3.55 | 5.81 | 5.11 | |
Accounts Payable Turnover |
1.87 | 0.92 | 1.52 | 1.70 | |
Inventory Turnover |
2.31 | 3.04 | 2.41 | 2.30 | |
Average Days of Payables |
230.04 | 587.42 | 236.20 | 183.54 | |
Days of Inventory on Hand |
166.93 | 121.35 | 160.25 | 150.81 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
43.58% | 38.59% | 31.90% | 29.38% | |
Selling, General and Administrative Expense of Revenue |
145.25% | 179.25% | 142.73% | 135.17% | |
Share Based Compensation of Revenue |
19.93% | 17.12% | 16.62% | 17.32% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.63 | 0.64 | 0.58 | |
Depreciation/Fixed assets |
2.94 | 2.97 | 2.88 | 2.54 | |
Capex/Depreciation |
(0.04) | (0.05) | (0.04) | (0.06) | |
Revenue per Share |
0.39 | 0.42 | 0.41 | 0.43 | |
Operating CF per Share |
(0.46) | (0.49) | (0.36) | (0.36) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(158.95%) | (188.09%) | (137.08%) | (144.63%) |
Columns are period end dates